Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Palantir Technologies received a new Buy rating from Loop Capital and continued bullish support from Wedbush on Thursday, despite recent market concerns over potential U.S. defense budget cuts.

U.S. defense stocks opened in the red on Thursday, Feb. 20 following reports that President Donald Trump’s administration has ...

Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing ETF market. Read more here.

Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...

Equities research analysts at Wedbush increased their FY2024 earnings per share estimates for shares of Cheesecake Factory in ...

Wedbush will sponsor its own ETFs to provide clients and investors with cost-effective, transparent investment options designed to meet modern portfolio construction needs. “ETF creation is a logical ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for ...

Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...